Lantheus (LNTH) Downgraded by ValuEngine

Lantheus (NASDAQ:LNTH) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Friday.

A number of other equities research analysts have also recently weighed in on the company. Zacks Investment Research raised Lantheus from a “hold” rating to a “strong-buy” rating and set a $18.00 price objective for the company in a research note on Thursday, August 3rd. Credit Suisse Group lifted their price objective on Lantheus from $19.00 to $23.00 and gave the company a “neutral” rating in a research note on Friday, November 3rd. Jefferies Group reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Lantheus in a research note on Thursday, October 12th. Wells Fargo & Company raised Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday, November 2nd. Finally, BidaskClub cut Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 17th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $24.50.

Shares of Lantheus (NASDAQ LNTH) opened at $21.85 on Friday. Lantheus has a one year low of $7.95 and a one year high of $24.10. The company has a quick ratio of 2.46, a current ratio of 2.96 and a debt-to-equity ratio of -3.41. The firm has a market capitalization of $819.51, a price-to-earnings ratio of 19.51, a PEG ratio of 1.73 and a beta of 0.94.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.04. Lantheus had a negative return on equity of 46.45% and a net margin of 9.59%. The business had revenue of $79.94 million during the quarter, compared to analysts’ expectations of $77.18 million. During the same period in the previous year, the firm posted $0.15 earnings per share. The company’s revenue was up 9.4% on a year-over-year basis. sell-side analysts predict that Lantheus will post 1.05 EPS for the current fiscal year.

In related news, insider Michael P. Duffy sold 20,000 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $16.45, for a total transaction of $329,000.00. Following the completion of the transaction, the insider now directly owns 184,218 shares of the company’s stock, valued at approximately $3,030,386.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael P. Duffy sold 11,917 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $21.63, for a total value of $257,764.71. Following the transaction, the insider now directly owns 152,301 shares of the company’s stock, valued at $3,294,270.63. The disclosure for this sale can be found here. Insiders have sold a total of 316,787 shares of company stock valued at $5,446,943 over the last three months. 2.30% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System grew its stake in Lantheus by 5.2% during the 3rd quarter. California State Teachers Retirement System now owns 48,609 shares of the medical equipment provider’s stock worth $865,000 after purchasing an additional 2,409 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Lantheus by 5.0% during the 3rd quarter. Rhumbline Advisers now owns 53,702 shares of the medical equipment provider’s stock worth $956,000 after acquiring an additional 2,560 shares in the last quarter. New York State Teachers Retirement System boosted its position in shares of Lantheus by 13.4% during the 3rd quarter. New York State Teachers Retirement System now owns 23,713 shares of the medical equipment provider’s stock worth $422,000 after acquiring an additional 2,800 shares in the last quarter. LS Investment Advisors LLC boosted its position in shares of Lantheus by 47.1% during the 3rd quarter. LS Investment Advisors LLC now owns 9,306 shares of the medical equipment provider’s stock worth $166,000 after acquiring an additional 2,981 shares in the last quarter. Finally, Cubist Systematic Strategies LLC boosted its position in shares of Lantheus by 22.4% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 21,915 shares of the medical equipment provider’s stock worth $390,000 after acquiring an additional 4,015 shares in the last quarter. 92.05% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/03/lantheus-lnth-downgraded-by-valuengine.html.

Lantheus Company Profile

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Lantheus Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply